Real‐World Efficacy and Drug Survival of Adalimumab in Australian Patients With Psoriasis
Australasian Journal of Dermatology · 2026
DOI: 10.1111/ajd.70024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Australasian Journal of Dermatology, 2026. Verfasst von N Punchihewa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Skin Health Institute, Carlton, Victoria, Australia. Hauptthemen laut MEDLINE: Adalimumab, Psoriasis. Die Arbeit nennt 15 Literaturangaben. Gefördert von: F & E Bauer Foundation.
Abstract (Originalsprache)
Background
Although adalimumab has shown strong efficacy and safety in clinical trials, real‐world evidence in Australian patients with moderate‐to‐severe chronic plaque psoriasis is limited. This study assessed adalimumab efficacy and drug survival in routine clinical practice, comparing outcomes with the Phase 3 REVEAL trial and its open‐label extension.
Methods
Data were extracted from the Australasian Psoriasis Registry for adults meeting Pharmaceutical Benefits Scheme criteria to be prescribed adalimumab for chronic plaque psoriasis. Baseline demographics, Psoriasis Area and Severity Index (PASI) scores and treatment history between June 2006 and March 2022 were analysed. Drug survival was evaluated using Kaplan–Meier and Cox regression.
Results
A total of 306 patients were included; 59.8% had prior biologic exposure compared to 12.8% in REVEAL. The mean baseline PASI was 24.1 and at 3 months, 63.5% achieved PASI75 while 33.6% achieved PASI90. PASI90 responses remained stable through 3 years and exceeded REVEAL extension rates beyond 18 months. Median drug survival was 27.9 months; survival was 97.7%, 78.6%, 63.7% and 51.0% at 3, 9, 15 and 27 months, respectively. Male sex and achieving PASI ≤ 2 predicted longer drug survival.
Conclusions
In Australian real‐world practice, adalimumab demonstrated sustained effectiveness and drug survival in patients with chronic plaque psoriasis comparable to RCTs, despite higher baseline disease severity and greater prior biologic exposure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Skin Health Institute, Carlton, Victoria, Australia.
- The University of Melbourne, Parkville, Victoria, Australia.
- St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
- Royal Melbourne Hospital, Parkville, Victoria, Australia.
- Southern Adelaide Health Network, South Australia, Australia.
- College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia.
ORCID-Profile: N Punchihewa, J M Armstrong, S Vogrin, J Frew
Förderung
- F & E Bauer Foundation
Zitieren
APA
Punchihewa, N., Nguyen, J. K., Armstrong, J. M., Vogrin, S., Dolianitis, C., Baker, C., Marshman, G., Frew, J., Wu, J., Lowe, P., & Foley, P. (2026). Real‐World Efficacy and Drug Survival of Adalimumab in Australian Patients With Psoriasis. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.70024
Vancouver
Punchihewa N, Nguyen JK, Armstrong JM, Vogrin S, Dolianitis C, Baker C, et al. Real‐World Efficacy and Drug Survival of Adalimumab in Australian Patients With Psoriasis. Australasian Journal of Dermatology. 2026. doi:10.1111/ajd.70024
BibTeX
@article{Punchihewa2026,
author = {Punchihewa, N and Nguyen, J K and Armstrong, J M and Vogrin, S and Dolianitis, C and Baker, C and Marshman, G and Frew, J and Wu, J and Lowe, P and Foley, P},
title = {Real‐World Efficacy and Drug Survival of Adalimumab in Australian Patients With Psoriasis},
journal = {Australasian Journal of Dermatology},
year = {2026},
doi = {10.1111/ajd.70024}
}
EUVIMED